



D. BORAL
— CAPITAL —

June 2025



\$7,000,000

Follow-On Offering

Co-Placement Agent



*For more information please
contact :*

Investment Banking

Gaurav Verma
Co-Head of Investment Banking
Direct: +1 (929) 528-0912
gverma@dboralcapital.com

Thomas DeLoache
Director, Investment Banking
Direct: +1 (929) 528-0767
wtdeLoache@dboralcapital.com

Nolan Munafo
Associate, Investment Banking
Direct: +1 (929) 528-0905
nmunafo@dboralcapital.com

Equity Capital Markets

Philip Wiederlight
Chief Operating Officer
Direct: +1 (929) 625-1539
pwiederlight@dboralcapital.com

Mark Iorio
Director, Equity Capital Markets
Direct: +1 (929) 528-0913
miorio@dboralcapital.com

D. Boral Capital Acted as Co-Placement Agent to Medicus Pharma Ltd. (Nasdaq: MDCX) in connection with its \$7.0 Million Follow-On Offering

Transaction Information

On June 2, 2025, Medicus Pharma Ltd. (Nasdaq: MDCX) (the "Company") today announced the closing of its previously announced follow-on offering of 2,260,000 units, on a "best-efforts" basis, at a price of \$3.10 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share. The warrants will have an exercise price of \$3.10 per share and will expire 5 years from the date of issuance. The common shares are listed on The Nasdaq Capital Market under the symbol "MDCX". The warrants will not trade on any securities exchange.

The Company intends to use any net proceeds from the offering to fund its Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch. The Company may also use the net proceeds of the offering to expand its exploratory phase 2 clinical trial to a pivotal trial and/or to expand its trials to cover other non-melanoma skin diseases. The company will use any remaining net proceeds for general corporate purposes and working capital.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.

D. Boral Capital LLC ("D. Boral") acted as a co-placement agent for the Offering.

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells.

For more information visit <https://medicuspharma.com/>.

About D. Boral Capital

D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.

A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately \$30 billion in capital since its inception in 2020, executing ~350 transactions across a broad range of investment banking products.

D. Boral Capital is a member of FINRA and SIPC.



D. BORAL
— CAPITAL —